Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i>-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014

Abstract

Compared with chemotherapy, crizotinib demonstrated a significantly higher IC-DCR in patients with tBM. Improvements in IC-TTP were not statistically significant in patients with or without tBM, although sensitivity to detect treatment differences in or between the two subgroups was low.